His major research interest is in rectal and anal cancer and in phase I, and translational research in chemoradiation.

He has more than 150 peer reviewed publications.

Current areas of research include the integration of immune checkpoint inhibitors into chemoradiation schedules in anal cancer and rectal cancer, the investigation of predictive factors for response and resistance to chemoradiation in anal and rectal cancer, DCE-MRI changes, and the optimal timing for surgery after chemoradiation.